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National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in 
the United Kingdom. 
Sir 
We read with interest the recent editorial on faecal microbiota transplantation for recurrent or 
refractory Clostridium difficile infection (CDI) in which Dr Goldberg summarizes the efficacy of this 
treatment but also the obstacles in the way of undertaking this treatment.
1
 Indeed although the 
National Institute of Health and Care Excellence advocate the use of faecal microbiota transplantation 
(FMT) for recurrent or refractory Clostridium difficile infection (CDI) when antibiotics fail, our perception 
is that it has not been widely adopted in the UK. Although the Medicines and Healthcare products 
Regulatory Agency (MHRA) recently announced that FMT falls within the definition of a medicinal 
product in the context of clinical trials, this is not the case for CDI treatment and in this context the 
practice of FMT has not yet been standardised or regulated in the UK.
2
 We conducted a national survey 
to explore current experience with FMT and challenges faced by hospitals in setting up this service. We 
invited gastroenterologists, microbiologists and infectious disease physicians in the UK to take part in 
national survey by completing an online questionnaire in 2015. 
A total of 255 responses were obtained, of which 204 were included from 120 microbiologists and 
infectious disease physicians and 84 gastroenterologists following exclusion of incomplete and invalid 
responses. The survey covered 130 independent sites including 112 acute hospital NHS Trusts in 
England, 9 in Scotland and 9 in Wales. We found that of these 130 sites only 28% (36/130) had ever 
performed FMT for refractory or recurrent CDI (Table 1). Furthermore, although 21 of these 36 sites 
reported having had experience of providing FMT for over one year, only seven sites had treated at least 
10 patients. Of the sites that delivered this treatment 24 made the product up on site while 12 obtained 
FMT from other sites to administer at their hospital. A map of sites currently performing FMT or not is 
shown in Figure 1. One site performed FMT for refractory ulcerative colitis in a single patient. There 
were no other indications for its use. 
Our survey showed that 94 independent sites did not perform FMT and of these 27 (29%) had referred 
their refractory or recurrent CDI patients elsewhere for FMT; primarily to Glasgow (in Scotland), 
Birmingham (in the English midlands) and Exeter (in south-west England). Of sites that were not 
undertaking FMT, 66 (70%) were keen to have support in setting up an FMT service for CDI locally. On 
surveying reasons for lack of local provision for FMT at these non-FMT sites, 42 (45%) believed that they 
were unable to do it due to lack of facilities and 36 (38%) did not know where to start. However only five 
(5%) felt reluctant to do it because of its perceived unpleasantness. Only a few physicians commented 
that they were not convinced with the evidence of its efficacy and safety, therefore would not 
recommend it for their patients.  
Our survey provides the most comprehensive representation of FMT service and delivery in UK to date 
and these findings uncover a surprising lack of uptake for a highly effective, cheap and safe treatment 
for refractory or recurrent CDI.
3
 With just over a quarter of sites in the UK performing FMT and less than 
one-third referring patients to other hospitals, it is clear that this geographical inconsistency in 
treatment availability needs to be urgently addressed. Consistent with a survey conducted three years 
ago,
4
 logistical hurdles, costs and local expertise continue to be the primary barriers in set up this service 
in hospitals in the UK. Despite the MHRA’s reasonably permissive approach on FMT as a treatment for 
CDI, there are considerable challenges and implications in setting up a safe, efficient and regulated FMT 
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service. This is especially with regard to donor screening (which can be laborious and expensive to 
perform) and preparation of stool prior to transplantation. The lack of protocols and guidelines for safe 
and regulated FMT preparation and delivery means it is likely there are significant differences in levels of 
governance amongst sites that perform FMT nationally.  
It was clear from the survey that despite these significant challenges faced by hospitals, most would 
welcome support in providing FMT. Similar to the OpenBiome service established in Boston which caters 
to over 500 hospitals in USA,
5
 a central or regional quality controlled and regulated FMT preparation, 
delivery and support service for the UK may be an appropriate and safe strategy.6 There needs to be 
agreed national guidelines and protocols for patient and donor selection and screening as well as FMT 
preparation and delivery based on current evidence for efficacy and safety.  Indeed a joint working 
group involving the Hospital Infection Society and the British Society of Gastroenterology are working on 
such guidelines. Additionally, there is an urgent need to establish a national registry of patients treated 
with FMT, in order to review long term outcome and safety data and improve our understanding of 
disease and treatment mechanisms. 
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Table 1: Results of survey of practice of faecal microbiota transplantation for Clostridium difficile 
infection in the United Kingdom 
  England Scotland Wales 
Total sites responding to survey 112 9 9 
Sites FMT performed in 32 1 3 
Sites performing FMT for > 1 year 17 1 3 
Sites performing FMT for < 1 year 15 0 0 
Sites that delivered FMT in  ≥ 10 patients  5 0 2 
Sites that delivered FMT in < 10 patients  27 1 1 
 
 
 
 
Figure 1: Map of sites of hospitals responding to the of survey of practice of faecal microbiota 
transplantation for Clostridium difficile infection in the United Kingdom 
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